Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Birch Pollen Allergy - Overview
Birch Pollen Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Birch Pollen Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Route of Administration
Assessment by Molecule Type
Birch Pollen Allergy - Companies Involved in Therapeutics Development
Allergy Therapeutics Plc
Anergis SA
Biomay AG
Desentum Oy
HAL Allergy BV
Polyrizon Ltd
Regeneron Pharmaceuticals Inc
Roxall Medizin GmbH
S-TARget therapeutics GmbH
Birch Pollen Allergy - Drug Profiles
Allergen for Birch Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
birch pollen allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-31 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pollinex Quattro Birch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-5713 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-5714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REGN-5715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SG-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccines for Birch Pollen Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Birch Pollen Allergy - Dormant Projects
Birch Pollen Allergy - Discontinued Products
Birch Pollen Allergy - Product Development Milestones
Featured News & Press Releases
Nov 01, 2019: Desentum will run a clinical trial on its allergy vaccine this winter supported by 4 M? of new investments
Oct 17, 2019: Mymetics announces new study to predict efficacy of Second- Generation COP Allergy Immunotherpy with Virosomes
Mar 18, 2019: Allergy Therapeutics’ birch pollen product fails to meet primary endpoint
Dec 13, 2018: Anergis reports positive preclinical proof-of concept data of the Second-Generation COP Allergy Vaccine
Sep 05, 2018: Anergis initiates development of second-generation COP Allergy Vaccines; announces publication of sustained efficacy data from Ph. IIb study follow-Up
Aug 14, 2018: HAL Allergy first company to achieve marketing authorisations in line with Therapieallergene-Verordnung (TAV) in Germany
Jun 14, 2017: Desentum has two presentations in EAACI 2017
May 10, 2017: Desentum is preparing to start clinical trials with birch pollen allergy vaccine
Mar 16, 2017: Allergy Therapeutics Announces First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study
May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy
May 09, 2016: Allergy Therapeutics Announces Positive Top-Line Results From the PQBirch204 Phase II Study for Birch-Induced Seasol Allergic Rhinitis
Sep 01, 2015: First patient recruited in Pollinex Quattro Birch dose ranging study in Germany and Austria
Mar 10, 2015: Positive Outcome of the PURETHAL Birch RUSH Study Results in an Approved, Accelerated up-dosing Regimen
May 12, 2013: Desentum: EARTO innovation prize to VTT
Mar 09, 2006: Stallergenes Reports Positive Study Results with Biomay?s Bet v 1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Birch Pollen Allergy, 2021
Number of Products under Development by Companies, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021


List of Tables


Number of Products under Development for Birch Pollen Allergy, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Birch Pollen Allergy - Pipeline by Allergy Therapeutics Plc, 2021
Birch Pollen Allergy - Pipeline by Anergis SA, 2021
Birch Pollen Allergy - Pipeline by Biomay AG, 2021
Birch Pollen Allergy - Pipeline by Desentum Oy, 2021
Birch Pollen Allergy - Pipeline by HAL Allergy BV, 2021
Birch Pollen Allergy - Pipeline by Polyrizon Ltd, 2021
Birch Pollen Allergy - Pipeline by Regeneron Pharmaceuticals Inc, 2021
Birch Pollen Allergy - Pipeline by Roxall Medizin GmbH, 2021
Birch Pollen Allergy - Pipeline by S-TARget therapeutics GmbH, 2021
Birch Pollen Allergy - Dormant Projects, 2021
Birch Pollen Allergy - Discontinued Products, 2021